Monday - June 01, 2026

Category Archives: Science

Glioblastoma Pipeline Drugs Report 2025: Promising Drugs, Advanced Treatment Approaches, Clinical Trials, and Leading Companies

DelveInsight’s “Glioblastoma Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Gthe lioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline … Continue reading →

Sleep Apnea Pipeline 2025: Emerging Drugs, Innovative Therapies, Ongoing Clinical Trials, and Key Companies Driving Next-Generation Treatments

DelveInsight’s, “Sleep Apnea Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Hypertension Pipeline Drugs Report 2025: Unlocking Future Growth with Breakthrough Therapies in Development

DelveInsight’s, “Hypertension Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics … Continue reading →

Microbiome Disease Pipeline Drugs Report 2025: Exploring the Emerging Therapies and Clinical Advancements Ahead

DelveInsight’s, “Microbiome Disease Pipeline Insight 2025” report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in the Microbiome Disease pipeline landscape. It covers the Microbiome Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Gastrointestinal Stromal Tumors Pipeline Drugs Report 2025: Investigating Innovative Modalities Driving Transformative Treatments

DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Dayhoff Technologies Ranked Best Microbiome Test

Scientists recognize Dayhoff as most accurate microbiome test using triple-sampling, immediate freezing, and research-grade shotgun metagenomics—setting new industry standard for consumer testing. DALLAS, TX – September 29, 2025 – Dayhoff Technologies, a clinical-grade microbiome testing company, today announced its consumer microbiome … Continue reading →

Diabetes Pipeline Drugs Report 2025 by DelveInsight: A Comprehensive Analysis of Emerging Therapeutics, Novel Drug Classes, and Strategic Advancements in Treatment Development

DelveInsight’s, “Diabetes Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics … Continue reading →

SMIC tests Shanghai Yuliangsheng’s DUV lithography equipment, potentially shifting the global semiconductor landscape

SMIC was testing a deep ultraviolet (DUV) lithography system produced by Shanghai Yuliangsheng. While seemingly a simple internal equipment test, this event could become a significant turning point in the restructuring of the global semiconductor industry. In September 2025, a … Continue reading →

Spinal Cord Injury Pipeline Drugs Report 2025: Comprehensive Insights into Emerging Therapies, Clinical Developments, and Future Market Opportunities | DelveInsight

DelveInsight’s “Spinal Cord Injury Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →